Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells
Methods in Cell Biology · 2026
DOI: 10.1016/bs.mcb.2025.10.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Methods in Cell Biology, 2026. Verfasst von Alexey V Sarapulov und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, United States. Hauptthemen laut MEDLINE: Flow Cytometry, CD8-Positive T-Lymphocytes, Neoplasms, Cytotoxicity, Immunologic. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Cancer immunotherapy approaches aim to instruct the immune system to eliminate tumor cells. Immune checkpoint blockade (ICB) therapies, such as anti-CTLA-4 and anti-PD-1, have significantly advanced the field, and other immunotherapeutic modalities are constantly being developed and tested in pre-clinical and clinical studies. One of the most important outcomes of cancer immunotherapy is efficient elimination of tumor cells by cytotoxic CD8+ T cells. Thus, accurate measurement of tumor cell sensitivity to T-cell-mediated killing is crucial for improving treatment development. This paper presents a flow cytometry-based protocol to assess antigen-specific CD8+ T-cell cytotoxicity using ovalbumin (OVA)-specific CD8+ T cells from OT-1 TCR transgenic mice and OVA-presenting tumor cell lines (either transduced with OVA or pulsed with a class-I-MHC-restricted OVA-derived peptide). This method minimizes contribution from non-antigen-mediated killing into readouts by incorporating non-target cells (not expressing/presenting-OVA cells) into co-cultures. The procedure also allows for the evaluation of T-cell-mediated cytotoxicity under various conditions and enables concurrent immunophenotyping of effector T cells and target tumor cells if desired. The protocol can be easily customized, offers advantages over methods that rely on luciferase-expressing tumor cell lines and provides versatility in detecting multiple parameters, making it a useful and valuable tool for advancing cancer immunotherapy research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, United States.
- Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, United States; IMP, Weill Cornell Graduate School of Medical Sciences, New York, NY, United States; Park…
Förderung
- NCI NIH HHS
Zitieren
APA
Sarapulov, A. V., Rodriguez, M. A., & Zappasodi, R. (2026). Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells. Methods in Cell Biology. https://doi.org/10.1016/bs.mcb.2025.10.016
Vancouver
Sarapulov AV, Rodriguez MA, Zappasodi R. Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells. Methods in Cell Biology. 2026. doi:10.1016/bs.mcb.2025.10.016
BibTeX
@article{Sarapulov2026,
author = {Sarapulov, Alexey V and Rodriguez, Marc-Anthony and Zappasodi, Roberta},
title = {Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells},
journal = {Methods in Cell Biology},
year = {2026},
doi = {10.1016/bs.mcb.2025.10.016}
}
EUVIMED